Nanalysis Scientific (CVE:NSCI) Trading Down 2%

Share on StockTwits

Nanalysis Scientific Corp. (CVE:NSCI) was down 2% on Wednesday . The stock traded as low as C$0.50 and last traded at C$0.50, approximately 175,500 shares were traded during trading. An increase of 215% from the average daily volume of 55,765 shares. The stock had previously closed at C$0.51.

The stock’s fifty day moving average price is C$0.47. The company has a debt-to-equity ratio of 9.12, a current ratio of 4.48 and a quick ratio of 4.10. The company has a market cap of $30.81 million and a P/E ratio of -44.55.

About Nanalysis Scientific (CVE:NSCI)

Nanalysis Scientific Corp., through its subsidiary, Nanalysis Corp., operates as an industrial technology company. The company engages in the development, manufacture, and sale of magnetic resonance analyzers for the pharmaceutical, biotech, chemical, security, food, and education industries. Its products include NMReady-60PRO, a dual-channel nuclear magnetic resonance (NMR) spectrometer for multinuclear academic, research, and QA/QC inquires; NMReady-60e that allows students to acquire NMR data on their own samples and process these results during the lab; AUTOsample-60, a top mounting autosampler; NMReady-flow NMR flow cell kits; NMReady-CONNECT spectrometer that provides data about an instrument's performance and allows the user to setup, launch, and monitor spectroscopy experiments; and NMR accessories.

Recommended Story: How can investors invest in the S&P/TSX Index?

Receive News & Ratings for Nanalysis Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanalysis Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

QuickLogic  Downgraded by Zacks Investment Research to Sell
QuickLogic Downgraded by Zacks Investment Research to Sell
Regeneron Pharmaceuticals  Upgraded to “Buy” by BidaskClub
Regeneron Pharmaceuticals Upgraded to “Buy” by BidaskClub
Proofpoint  Raised to “Buy” at BidaskClub
Proofpoint Raised to “Buy” at BidaskClub
Omeros  Upgraded at BidaskClub
Omeros Upgraded at BidaskClub
360 Finance  Rating Increased to Buy at ValuEngine
360 Finance Rating Increased to Buy at ValuEngine
Kiniksa Pharmaceuticals  Downgraded by Zacks Investment Research to “Sell”
Kiniksa Pharmaceuticals Downgraded by Zacks Investment Research to “Sell”


 
© 2006-2020 Zolmax.